A new type of drugs called SGLT2 inhibitors is currently being studied by Bristol-Myers Squibb and AstraZeneca. The two companies worked together to develop this class of drugs in which Dapagliflozin is one of.
What the Studies Show
Dr. Clifford J. Bailey is a professor at Aston University in Birmingham, England. He is quoted as saying, "It works through an entirely different mechanism than any other diabetes drugs currently available, and you can add it on to other treatments and get an additional benefit. Plus as far as we can see, it can be used at any stage in the disease process."
As the patients blood sugar level become more normal the weight loss benefit becomes less and eventually non-existent with the use of the medication However, during the initial phases of the medication weight loss is a big factor. As many doctors and researchers believe that, a person’s weight plays a pivotal role in developing and managing diabetes.
How Dapagliflozin Works
Aside from controlling the glucose levels, it secretes the excessive amount of sugar in the body through the urine resulting in weight loss. Many people questioned if the weight loss was merely water weight. It is not the people who participated in the 24-week clinical study had smaller waist lines indicating it was fat being released from the body not water.
If all goes well the medication is due to be approved and released to the public in 2012.
Follow and Share InformationAboutDiabetes.com